top of page
shutterstock_255876943_drug discovery d3

ISNTD D3V
Drug discovery, development & vaccines
for neglected tropical diseases

Online

Dec 3 2025

#ISNTDd3

#beatNTDs

Introduction

ISNTD D3V 2025 takes a closer look at how progress in drug discovery and vaccines in the field of Neglected Tropical Diseases is critical is supporting ambitious control and elimination targets, and shares some of the recent updates and challenges in the pipeline for drugs and vaccines for NTDs. This series of talks will address the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development. 

​

Programme

​​

Topics covered include:

  • Pipeline for drug discovery in NTDs

  • Next-Gen Therapies: Genomics, AI and the Future of NTD Drug Discovery

  • Collaborate to Cure: Building Global Partnerships for NTD Therapeutics 

  • Can Vaccines Turn the Tide on Neglected & Tropical Diseases?

​

​​​​Revisit ISNTD d³ 2024

Register here 

Thanks for submitting! Your registration has been successful.

11.00-12.30 UTC | Advancing Therapies: Updates and Innovation in NTD Drug Discovery

Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment

Dr Godwin Ebiloma (Lecturer in Biochemistry & Pharmaceutical Science, University of Salford, Manchester UK)

​

Recent progress in snakebite therapeutics

Prof Nicholas Casewell (Centre for Snakebite Research and Interventions, Liverpool School of Tropical Medicine, Liverpool, UK)

​

Moxidectin combination therapies for lymphatic filariasis

 

Expanding the frontiers of schistosomiasis treatment - the promise of nanoparticle-based therapies 

Ramya Raghavan (Sri Sathya Sai University for Human Excellence, Karnataka, India)​

​​

​

​

12.45-14.15 UTC | Can Vaccines Turn the Tide on Neglected & Tropical Diseases?

Identifying WHO global priority endemic pathogens for vaccine research and development (R&D): an objective of the Immunization Agenda 2030 

Dr Bernadette Abela-Ridder (Team Leader, Neglected Zoonotic Diseases, World Health Organization)

​

Control measures for neglected tropical diseases: vaccine updates

Dr Vivek Chavda (Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad, India)

​

Key Milestones in Evolution of Biopharmaceutical & Vaccine Manufacturing

Dr Lionel Gerentes (Head of Viral & Bacterial Scientific Excellence , MSAT Vaccine, Sanofi)

​

Pre-clinical studies of Schistosoma mansoni vaccines

Dr Emma Houlder (Leiden University Center for Infectious Diseases, The Netherlands)

​

​

​

14.30-16.00 UTC | Spotlight on Kinetoplastid Parasitic Diseases and Bacterial Infections: From Chemical Biology to Therapeutic Leads
 

Chemical Biology-Enabled Target Profiling in Infectious Diseases
Dr. Gustavo F. Mercaldi (Senior Researcher - Division of Immunity and Pathogens, Brazilian Biosciences National Laboratory)


Novel Fluorometric Enzyme-Coupled Arginase Assay for Target-Based Therapeutic Drug Discovery
Ms. Matheson J. Bray (Undergraduate Researcher, University of South Carolina Beaufort)


Exploring T. cruzi IMPDH as a Promising Target Through Chagas Box Screening and AVN-944 Inhibition
Dr. Angel Eduardo Lobo-Rojas (Adjunct Researcher - Division of Immunity and Pathogens, Brazilian Biosciences National Laboratory)


Exploration of 3-Nitro-2-Phenyl-2H-Chromene Analogues for Potent Anti-Trypanosomal Activity
Dr. Edward L. D'Antonio (Professor of Biochemistry and Structural Biology, University of South Carolina Beaufort)
 

​

​

bottom of page